Literature DB >> 9781568

Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine.

R N Mandler1, W Ahmed, J E Dencoff.   

Abstract

Seven newly diagnosed patients with Devic's neuromyelitis optica were treated with long-term prednisone and azathioprine, and were followed every 2 months for at least 18 months. Their Expanded Disability Status Scale score improved significantly (mean at baseline, 9; mean at 18 months, 3; p < 0.005), and no relapses occurred for more than 18 months. Multicenter controlled studies are needed to prove the efficacy of this therapeutic regimen.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9781568     DOI: 10.1212/wnl.51.4.1219

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  59 in total

Review 1.  [Administration of intravenous immunoglobulins in neurology. An evidence-based consensus: update 2010].

Authors:  M Stangel; R Gold
Journal:  Nervenarzt       Date:  2011-04       Impact factor: 1.214

2.  Treatment of neuromyelitis optica: current debate.

Authors:  Tomoko Okamoto; Masafumi Ogawa; Youwei Lin; Miho Murata; Sachiko Miyake; Takashi Yamamura
Journal:  Ther Adv Neurol Disord       Date:  2008-07       Impact factor: 6.570

3.  Development of extensive brain lesions following interferon beta therapy in relapsing neuromyelitis optica and longitudinally extensive myelitis.

Authors:  Yuko Shimizu; Kazumasa Yokoyama; Tatsuro Misu; Toshiyuki Takahashi; Kazuo Fujihara; Seiji Kikuchi; Yasuto Itoyama; Makoto Iwata
Journal:  J Neurol       Date:  2007-11-21       Impact factor: 4.849

4.  Efficacy of tacrolimus in Sjögren's syndrome-associated CNS disease with aquaporin-4 autoantibodies.

Authors:  Taku Fukuda; Hirokazu Shiraishi; Tatsufumi Nakamura; Keiko Tanaka; Hideki Nakamura; Akira Tsujino; Yoshihiro Nishiura; Toshiro Yoshimura; Masakatsu Motomura; Katsumi Eguchi
Journal:  J Neurol       Date:  2009-05-26       Impact factor: 4.849

5.  Neuromyelitis optica - an update: 2007-2009.

Authors:  Anu Jacob
Journal:  Ann Indian Acad Neurol       Date:  2009-10       Impact factor: 1.383

6.  [Therapeutic options for autoimmune encephalomyelitis].

Authors:  N Borisow; H Prüss; F Paul
Journal:  Nervenarzt       Date:  2013-04       Impact factor: 1.214

Review 7.  What is new in the treatment of multiple sclerosis?

Authors:  B Weinstock-Guttman; L D Jacobs
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

8.  CSF pleocytosis and expansion of spinal lesions in Japanese multiple sclerosis with special reference to the new diagnostic criteria.

Authors:  Toshiyuki Fukazawa; Seiji Kikuchi; Ryuji Miyagishi; Yusei Miyazaki; Hikoaki Fukaura; Ichiro Yabe; Takeshi Hamada; Kunio Tashiro; Hidenao Sasaki
Journal:  J Neurol       Date:  2005-03-06       Impact factor: 4.849

9.  Aquaporin-4 autoantibodies in neuromyelitis optica spectrum disorders: comparison between tissue-based and cell-based indirect immunofluorescence assays.

Authors:  Koon H Chan; Jason S C Kwan; Philip W L Ho; Jessica W M Ho; Andrew C Y Chu; David B Ramsden
Journal:  J Neuroinflammation       Date:  2010-09-07       Impact factor: 8.322

10.  Patient with neuromyelitis optica and inflammatory demyelinating lesions comprising whole spinal cord from C2 level till conus: case report.

Authors:  Zeljka Petelin Gadze; Sanja Hajnsek; Silvio Basic; Davor Sporis; Goran Pavlisa; Sibila Nankovic
Journal:  BMC Neurol       Date:  2009-10-23       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.